Inhibition of FcRn with rozanolixizumab in adults with immune thrombocytopenia: Two randomised, double‐blind, placebo‐controlled phase 3 studies and their open‐label extension. Here, FCGRT is linked to autoimmune thrombocytopenic purpura.